Table 10.
Effect of 50–400 mg/kg/day of CVE on the serum lipid profile of DOX-treated rats.
| Groups | Serum lipids | ||||
|---|---|---|---|---|---|
| TG (mmol/l) | TC (mmol/l) | HDL-c (mmol/l) | LDL-c (mmol/l) | VLDC-c (mmol/l) | |
| I | 1.3 ± 0.1c+ | 2.3 ± 0.1a+ | 0.6 ± 0.0 | 1.2 ± 0.1 | 1.3 ± 0.1c+ |
| II | 0.8 ± 0.2d− | 1.8 ± 0.2d− | 0.6 ± 0.0 | 0.9 ± 0.1d− | 0.4 ± 0.1f− |
| III | 0.8 ± 0.1d− | 2.3 ± 0.1 | 0.7 ± 0.0 | 1.3 ± 0.1 | 0.5 ± 0.1f− |
| IV | 1.1 ± 0.1 | 2.3 ± 0.1 | 0.6 ± 0.0 | 1.2 ± 0.1 | 0.5 ± 0.1f− |
| V | 0.8 ± 0.1d− | 2.3 ± 0.1 | 0.6 ± 0.0 | 1.3 ± 0.1 | 0.4 ± 0.0f− |
| VI | 1.0 ± 0.1d− | 2.3 ± 0.2 | 0.6 ± 0.0 | 1.2 ± 0.1 | 0.5 ± 0.1f− |
| VII | 0.9 ± 0.1d− | 2.1 ± 0.1 | 0.6 ± 0.0 | 1.1 ± 0.1 | 0.4 ± 0.0f− |
| VIII | 0.6 ± 0.1 | 2.0 ± 0.1 | 0.6 ± 0.0 | 1.1 ± 0.0 | 0.3 ± 0.0 |
a+, c+Significant increases at p < 0.5 and p < 0.0001, respectively, when compared to the untreated negative (normal) control value. d−,f−Significant decreases at p < 0.05 and p < 0.0001 when compared to the untreated positive (doxorubicin treated only) control values, respectively.